Viridian Therapeutics received early FDA approval for Lumvoa (veligrotug), a treatment for thyroid eye disease (TED), ahead of the June 30 deadline. Lumvoa offers advantages over Amgen's Tepezza, including a shorter infusion course, chronic TED data on its label, and immediate market availability, positioning Viridian for commercial success. While management is cautious about near-term revenue, the company also shows promise with other pipeline drugs like VRDN-008 and FcRn antibodies, potentially expanding into Graves' disease treatment. This approval marks a significant milestone for Viridian's growth in the biotech sector focused on TED therapies.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
